FilingsTodayPharmaResearch
At a glance
PharmaResearch filed 41 disclosures in the last 12 months, including 4 insider, 4 5% holder and 3 earnings. The most recent key filing was on Oct 2.
Revenue for 2025 was ₩536B, up 53.2% on 2024. Operating margin was 40% against 36% a year earlier. Debt was 44% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩325B and operating profit of ₩124B.
The 2025 annual report lists 526 employees with an average tenure of 3.3 years and average pay of ₩68.5M, #639 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩266M each on average. It paid ₩3,700 per common share in cash dividends, against ₩1,100 a year earlier (+236.4%). 정상수 and related parties held 31.37% at year end.
From the 2025 annual report
Staff: 526 (279 men, 247 women), of whom 28 on fixed-term contracts. Total pay for the year: ₩36.4B. Directors and auditors: 9, paid ₩2.4B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩3,700 | ₩1,100 | ₩950 |
| Payout ratio | 25.9% | 14.6% | 12.7% |
| Yield (as filed) | 0.90% | 0.40% | 0.90% |
| Total cash dividends | ₩42.8B | ₩13.4B | ₩9.7B |
Largest shareholder
정상수 holds 30.80%; with 9 related parties the group holds 31.37% of common shares at year end (from 34.34% at the start of the year).
Individuals paid ₩500M or more
| 강기석 前 대표이사 | ₩615M |
| 손지훈 대표이사 | ₩564M |
| 김신규 前 대표이사 | ₩543M |
Auditor: 회계법인 리안 · opinion: Unqualified.
Rankings: Operating margin #12 of 1,376 · Dividend growth #19 of 917 · Revenue growth #46 of 1,376
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.